Want to see ARQT full AI Analyst Report?
ARQT Stock Chart & Stats
$24.53
-$0.25(-1.59%)
At close: 4:00 PM EST
$24.53
-$0.25(-1.59%)
Day’s Range― - ―
52-Week Range$13.70 - $31.77
Previous CloseN/A
Volume446.87K
Average Volume (3M)1.71M
Market Cap
$3.56B
Enterprise Value$2.94K
Total Cash (Recent Filing)$224.00M
Total Debt (Recent Filing)$114.67M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Aug 05, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding125,083,374
10 Day Avg. Volume1,553,668
30 Day Avg. Volume1,710,178
Financial Highlights & Ratios
PEG Ratio2.52
Price to Book (P/B)19.50
Price to Sales (P/S)9.82
P/FCF Ratio-585.47
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$34.86Price Target Upside42.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.22
Revenue Forecast (FY)$499.75M
Bulls Say, Bears Say
Bulls Say
Very High Gross MarginsSustained ~91% gross margins imply strong product economics for topical franchises, enabling scale-driven operating leverage. High margins provide durable capacity to absorb commercial and R&D investment and can support long-term profitability even if net realizations face pressure from rebates.
Positive Operating And Free Cash FlowA move to positive OCF/FCF represents a structural inflection: it reduces reliance on equity financing, funds commercialization and pipeline activities internally, and improves financial flexibility. If sustained, positive cash generation materially lowers dilution risk and supports growth investments.
Commercial Momentum And Share GainsRobust YoY revenue growth, high prescription levels and rising branded share indicate durable market adoption and a strong commercial franchise. Continued script growth and maintained guidance suggest the sales organization and formulary position can sustain revenue expansion over the next several quarters.
Bears Say
Substantial Gross-to-net DiscountsPersistent gross-to-net in the low-to-mid 50s materially reduces net realized price and can compress margins as sales scale. This structural payer-driven discounting makes profitability sensitive to formulary position shifts and requires sustained pricing/payer strategy to protect long-term margins.
Limited Medicare Part D AccessConstrained Part D coverage materially limits near-term addressable market among Medicare patients and slows uptake in older populations. Expanding Part D inclusion is a multi-plan, multi-quarter process, delaying revenue upside and making growth dependent on payer negotiations and time-consuming formulary additions.
Debt And Contingent Financing RelianceWhile cash balances are healthy, the company maintains meaningful debt and a near-term draw option, indicating reliance on committed financing if cash flow weakens. This structural contingency can increase leverage risk and constrain strategic flexibility if operating performance falls short of expectations.
Arcutis Biotherapeutics News
ARQT FAQ
What was Arcutis Biotherapeutics Inc’s price range in the past 12 months?
Arcutis Biotherapeutics Inc lowest stock price was $13.70 and its highest was $31.77 in the past 12 months.
What is Arcutis Biotherapeutics Inc’s market cap?
Arcutis Biotherapeutics Inc’s market cap is $3.56B.
When is Arcutis Biotherapeutics Inc’s upcoming earnings report date?
Arcutis Biotherapeutics Inc’s upcoming earnings report date is Aug 05, 2026 which is in 15 days.
How were Arcutis Biotherapeutics Inc’s earnings last quarter?
Arcutis Biotherapeutics Inc released its earnings results on May 06, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.064 by -$0.026.
Is Arcutis Biotherapeutics Inc overvalued?
According to Wall Street analysts Arcutis Biotherapeutics Inc’s price is currently Undervalued.
Does Arcutis Biotherapeutics Inc pay dividends?
Arcutis Biotherapeutics Inc does not currently pay dividends.
What is Arcutis Biotherapeutics Inc’s EPS estimate?
Arcutis Biotherapeutics Inc’s EPS estimate is 0.05.
How many shares outstanding does Arcutis Biotherapeutics Inc have?
Arcutis Biotherapeutics Inc has 125,083,374 shares outstanding.
What happened to Arcutis Biotherapeutics Inc’s price movement after its last earnings report?
Arcutis Biotherapeutics Inc reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.064. Following the earnings report the stock price went down -14.522%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics Inc?
Currently, no hedge funds are holding shares in ARQT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcutis Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.86 (42.10% Upside)
$34.86 (42.10% Upside)
Blogger Sentiment
Bullish
ARQT Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 481.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $157.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
84.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
33.68%
Trailing 12-Months
Company Description
Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
ARQT Stock 12 Month Forecast
Average Price Target
$34.86
▲(42.10% Upside)
Technical Analysis
Travere Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
8.56% Insiders
16.09% Mutual Funds
0.65% Other Institutional Investors
60.47% Public Companies and
Individual Investors